Automating MEDITECH Mavyret Prior Authorization Workflows

Klivira streamlines the complex process of MEDITECH Mavyret prior authorization, integrating directly with your EMR to automate data retrieval and submission for this critical Hepatitis C treatment.

Managing prior authorizations for high-volume, high-cost drugs like Mavyret within a MEDITECH environment presents unique operational challenges for revenue cycle directors and PA coordinators. The variability across MEDITECH product lines, coupled with specific clinical documentation requirements, often leads to manual processes and delays. Klivira provides a focused solution to mitigate these inefficiencies.

Navigating Mavyret PA Workflows within MEDITECH Expanse

For MEDITECH Expanse customers, the prior authorization workflow for Mavyret typically initiates at the point of order entry. Clinicians place orders within the Orders activity, which can trigger the need for an ePA submission. Klivira integrates into this flow, often leveraging SMART App Launch capabilities within Expanse to provide a seamless experience for PA coordinators, reducing context switching and manual data entry.

Strategic Data Extraction for Mavyret Prior Authorizations

Effective Mavyret prior authorization requires precise clinical documentation, including diagnosis, lab results, and treatment history. Klivira utilizes MEDITECH's integration surfaces, primarily FHIR R4 APIs for Expanse and modern 6.x deployments, to extract relevant US Core clinical resources. For legacy MEDITECH Magic or C/S environments, HL7 v2 interfaces remain a critical channel for accessing ADT, ORM/ORU, and MDM data essential for a complete PA packet.

Pharmacy Benefit vs. Medical Benefit for Hepatitis C Drugs

Hepatitis C treatments like Mavyret can fall under either the pharmacy benefit or the medical benefit, depending on the payer, site of care, and specific drug formulation. This dual-benefit landscape necessitates flexible submission pathways. Klivira supports both ePA submissions via NCPDP SCRIPT for pharmacy benefit drugs and X12 278 transactions or direct payer portal submissions for medical benefit cases, ensuring comprehensive coverage for Mavyret.

Optimizing Documentation for Mavyret PA Success

Klivira's platform is designed to identify and gather the specific documentation required for Mavyret prior authorizations from MEDITECH. This includes clinical notes from the Documentation module, relevant entries from the Problem List, and lab results, all critical for demonstrating medical necessity. Our system streamlines the assembly of these artifacts, reducing the burden on PA coordinators and improving the completeness of submissions.

Klivira's Integration Approach with MEDITECH

Klivira engages with MEDITECH's integration capabilities through channels like the Greenfield Workspace, which provides access to FHIR R4 APIs for Expanse. We acknowledge the product-line variability across MEDITECH deployments (Expanse, 6.x, C/S, Magic) and design our integrations to adapt, often incorporating HL7 v2 where FHIR is less prevalent. This ensures robust data exchange and workflow automation across diverse MEDITECH footprints.

Frequently asked questions

How does Klivira integrate with MEDITECH for Mavyret prior authorizations?

Klivira integrates with MEDITECH primarily through FHIR R4 APIs available via the Greenfield Workspace for Expanse and modern 6.x deployments. For legacy MEDITECH environments, we also leverage established HL7 v2 interfaces to ensure comprehensive data exchange. This allows for automated data extraction and workflow initiation directly from the EMR.

What clinical data does Klivira pull from MEDITECH for Mavyret PA?

For Mavyret prior authorizations, Klivira extracts essential clinical data from MEDITECH, including patient demographics, diagnoses from the Problem List, relevant lab results (e.g., HCV RNA, genotype), and supporting clinical notes from the Documentation module. This data is critical for building a complete and accurate PA submission to payers.

Does Mavyret prior authorization typically fall under pharmacy or medical benefit?

Mavyret, as a Hepatitis C treatment, can fall under either pharmacy or medical benefit, depending on the specific payer, patient's plan, and administration setting. Klivira's platform is equipped to handle both scenarios, supporting ePA submissions via NCPDP SCRIPT for pharmacy benefits and X12 278 or payer portal submissions for medical benefits.

How does Klivira handle different MEDITECH product lines (Expanse vs. legacy) for Mavyret PAs?

Klivira's integration strategy accounts for the significant product-line variability within MEDITECH. While we leverage modern FHIR R4 and SMART App Launch for Expanse, we also maintain capabilities for HL7 v2 integrations to support customers on legacy platforms like 6.x, C/S, and Magic. This ensures broad compatibility and consistent PA automation across your MEDITECH footprint.

Can Klivira write back Mavyret PA status to MEDITECH?

Klivira supports write-back of prior authorization status and documents to MEDITECH, enhancing visibility within the EMR. Specific write capabilities, such as depositing PA packets as DocumentReference entries or updating workflow tasks, are verified per customer's MEDITECH product line and configuration to ensure seamless integration and compliance.